Lymphangioleiomyomatosis (LAM)

Lymphangioleiomyomatosis (LAM) is a cystic lung disease that may progressively destroy the lung structure. Alterations in the lymphatic system and renal tumors are further characteristics of the disease. LAM patients may suffer from a progressively impaired lung function and dyspnea. Pneumothorax is a known complication, typically precedes or leads to diagnosis of LAM and requires sometimes-surgical intervention.
LAM is a rare lung disease (5 out of 1 mio.) and affects mainly woman in childbearing age. Diagnosis is typically delayed many years and experts with experience in treatment and follow-up are rare.
mTOR-Inhibitors such as Sirolimus allow to stabilize or slow down decrease of lung function and improve some measures of life in LAM.

We care for more than 20 patients with LAM and work together with national and international experts in the field. We are part of the tuberous sclerosis network of Zurich.

Extensive information can be found on the Webside of the LAM foundation

For further information:

PD Dr. med. Christian Clarenbach
Klinik für Pneumologie
UniversitätsSpital Zürich
Rämistrasse 100
8091 Zürich
christian.clarenbach@usz.ch

Last update: 21.06.2018 | Person responsible:
Professor Malcolm Kohler, MD